Travere Therapeutics (TVTX) Income towards Parent Company: 2011-2025
Historic Income towards Parent Company for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $25.7 million.
- Travere Therapeutics' Income towards Parent Company rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
- As of Q3 2025, Travere Therapeutics' Income towards Parent Company stood at $25.7 million, which was up 301.54% from -$12.8 million recorded in Q2 2025.
- Travere Therapeutics' Income towards Parent Company's 5-year high stood at $240.0 million during Q3 2023, with a 5-year trough of -$88.8 million in Q4 2021.
- In the last 3 years, Travere Therapeutics' Income towards Parent Company had a median value of -$100,000 in 2024 and averaged $21.4 million.
- Over the last 5 years, Travere Therapeutics' Income towards Parent Company had its largest YoY gain of 25,806.00% in 2025, and its largest YoY loss of 39,925.24% in 2025.
- Quarterly analysis of 5 years shows Travere Therapeutics' Income towards Parent Company stood at -$88.8 million in 2021, then soared by 122.32% to $19.8 million in 2022, then slumped by 107.96% to -$1.6 million in 2023, then skyrocketed by 100.25% to $4,000 in 2024, then spiked by 25,806.00% to $25.7 million in 2025.
- Its Income towards Parent Company stands at $25.7 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$41.2 million for Q1 2025.